# Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

> **NCT00543439** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 66 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** Moroctocog alfa (AF-CC)
- **BIOLOGICAL:** Moroctocog alfa (AF-CC)

## Key facts

- **NCT ID:** NCT00543439
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2018-04
- **Final completion:** 2018-04
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2019-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00543439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00543439, "Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00543439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*